Multifaceted polo-like kinases: Drug targets and antitargets for cancer therapy

Nature Reviews Drug Discovery

Volumn 9, Issue 8, 2010, Pages 643-660

  Strebhardt, Klaus ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO N (2,5 DIBROMOPHENYL) 3 HYDROXYCROTONAMIDE; 4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; AURORA A KINASE; BI 6727; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLAPOLIN 1; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; DAP 81; GSK 461364; GW 843682X; HMN 176; HMN 214; NMS P 937; ON 01910; PHA 680626; POLO LIKE KINASE; POLO LIKE KINASE 1; POLO LIKE KINASE 2; POLO LIKE KINASE 3; POLOXIN; POLOXIPAN; PROTEIN MDM2; PROTEIN P53; PROTEIN SERINE THREONINE KINASE INHIBITOR; PURPUROGALLIN; SUMO PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BONE PAIN; BREAST CANCER; CANCER INHIBITION; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; HUMAN; HYPERGLYCEMIA; IC 50; INFECTION; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEOPLASM; NEUROPATHY; NEUTROPENIA; NONHUMAN; PAIN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77955167321     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3184     Document Type: Review

References (266)

1. Sunkel, C. E. & Glover, D. M. polo, a mitotic mutantof Drosophila displaying abnormal spindle poles. J. Cell Sci. 89 (Pt 1), 25-38 (1988). This paper describes the mitotic phenotype of cellshomozygous for mutant alleles of the locus polo.
2. Llamazares, S. et al. polo encodes a protein kinasehomolog required for mitosis in Drosophila. GenesDev. 5, 2153-2165 (1991).
3. Glover, D. M., Hagan, I. M. & Tavares, A. A. Polo-likekinases: a team that plays throughout mitosis. GenesDev. 12, 3777-3787 (1998).
4. Barr, F. A., Sillje, H. H. & Nigg, E. A. Polo-like kinasesand the orchestration of cell division. Nature Rev. Mol. Cell Biol. 5, 429-440 (2004).
5. Andrysik, Z. et al. The novel mouse polo-like kinase 5responds to DNA damage and localizes in thenucleolus. Nucleic Acids Res. 38, 2931-2943 (2010).
6. Clay, F. J., McEwen, S. J., Bertoncello, I., Wilks, A. F. & Dunn, A. R. Identification and cloning of a proteinkinase-encoding mouse gene, Plk, related to the pologene of Drosophila. Proc. Natl Acad. Sci. USA 90,4882-4886 (1993).
7. van de Weerdt, B. C. & Medema, R. H. Polo-likekinases: a team in control of the division. Cell Cycle 5,853-864 (2006).
8. Petronczki, M., Lenart, P. & Peters, J. M. Polo on therise\from mitotic entry to cytokinesis with Plk1. Dev. Cell 14, 646-659 (2008).
9. Takaki, T., Trenz, K., Costanzo, V. & Petronczki, M. Polo-like kinase 1 reaches beyond mitosis\cytokinesis, DNA damage response, and development. Curr. Opin. Cell Biol. 20, 650-660 (2008).
10. Archambault, V. & Glover, D. M. Polo-like kinases:conservation and divergence in their functions andregulation. Nature Rev. Mol. Cell Biol. 10, 265-275(2009).
11. Barr, F. A. & Gruneberg, U. Cytokinesis: placingand making the final cut. Cell 131, 847-860(2007). References 3, 4, 7-11 are excellent reviews onthe multiple roles of PLK1 and its phylogeneticcounterparts during mitosis.
12. Holtrich, U. et al. Induction and down-regulation ofPLK, a human serine/threonine kinase expressed inproliferating cells and tumors. Proc. Natl Acad. Sci. USA 91, 1736-1740 (1994). This report describes for the first time the elevatedlevels of PLK1 in human cancer and initiated manyfollow-on studies analysing the expressionsignature of PLK1 in a broad spectrum of humantumours.
13. Lane, H. A. & Nigg, E. A. Antibody microinjectionreveals an essential role for human polo-likekinase 1 (Plk1) in the functional maturation ofmitotic centrosomes. J. Cell Biol. 135, 1701-1713(1996).
14. Cogswell, J. P., Brown, C. E., Bisi, J. E. & Neill, S. D. Dominant-negative polo-like kinase 1 induces mitoticcatastrophe independent of cdc25C function. CellGrowth Differ. 11, 615-623 (2000).
15. Spankuch-Schmitt, B. et al. Downregulation of humanpolo-like kinase activity by antisense oligonucleotidesinduces growth inhibition in cancer cells. Oncogene21, 3162-3171 (2002).
16. Spankuch-Schmitt, B., Bereiter-Hahn, J., Kaufmann, M. & Strebhardt, K. Effect of RNA silencing of polo-likekinase 1 (PLK1) on apoptosis and spindle formationin human cancer cells. J. Natl. Cancer Inst. 94,1863-1877 (2002).
17. Liu, X. & Erikson, R. L. Activation of Cdc2/cyclin B andinhibition of centrosome amplification in cells depletedof Plk1 by siRNA. Proc. Natl Acad. Sci. USA 99,8672-8676 (2002).
18. Strebhardt, K. & Ullrich, A. Targeting polo-likekinase 1 for cancer therapy. Nature Rev. Cancer 6,321-330 (2006).
19. Strebhardt, K. & Ullrich, A. Paul Ehrlich's magic bulletconcept: 100 years of progress. Nature Rev. Cancer 8,473-480 (2008).
20. Schoffski, P. Polo-like kinase (PLK) inhibitors inpreclinical and early clinical development in oncology. Oncologist 14, 559-570 (2009).
21. McInnes, C., Mezna, M. & Fischer, P. M. Progress inthe discovery of polo-like kinase inhibitors. Curr. Top. Med. Chem. 5, 181-197 (2005).
22. Xie, S. et al. Reactive oxygen species-inducedphosphorylation of p53 on serine 20 is mediated inpart by polo-like kinase 3. J. Biol. Chem. 276,36194-36199 (2001).
23. Xie, S. et al. Plk3 functionally links DNA damage to cellcycle arrest and apoptosis at least in part via the p53pathway. J. Biol. Chem. 276, 43305-43312 (2001).
24. Shimizu-Yoshida, Y. et al. Radiation-inducible hSNKgene is transcriptionally regulated by p53 bindinghomology element in human thyroid cells. Biochem. Biophys. Res. Commun. 289, 491-498 (2001).
25. Hanahan, D. & Weinberg, R. A. The hallmarks ofcancer. Cell 100, 57-70 (2000).
26. Luo, J., Solimini, N. L. & Elledge, S. J. Principlesof cancer therapy: oncogene and non-oncogeneaddiction. Cell 136, 823-837 (2009).
27. Yuan, J. et al. Polo-like kinase, a novel marker forcellular proliferation. Am. J. Pathol. 150, 1165-1172(1997).
28. Lowery, D. M. et al. Proteomic screen defines thePolo-box domain interactome and identifies Rock2as a Plk1 substrate. EMBO J. 26, 2262-2273(2007).
29. Lee, K. S., Grenfell, T. Z., Yarm, F. R. & Erikson, R. L. Mutation of the polo-box disrupts localization andmitotic functions of the mammalian polo kinase Plk. Proc. Natl Acad. Sci. USA 95, 9301-9306 (1998). This report describes the first example of afunctional analysis of the polo-box showing thatthis unique module regulates the subcellularlocalization of PLK1.
30. Lee, K. S., Song, S. & Erikson, R. L. The polo-boxdependentinduction of ectopic septal structures bya mammalian polo kinase, plk, in Saccharomycescerevisiae. Proc. Natl Acad. Sci. USA 96,14360-14365 (1999).
31. Song, S., Grenfell, T. Z., Garfield, S., Erikson, R. L. &Lee, K. S. Essential function of the polo box of Cdc5 insubcellular localization and induction of cytokineticstructures. Mol. Cell Biol. 20, 286-298 (2000).
32. Seong, Y. S. et al. A spindle checkpoint arrest and acytokinesis failure by the dominant-negative polo-boxdomain of Plk1 in U-2 OS cells. J. Biol. Chem. 277,32282-32293 (2002).
33. Reynolds, N. & Ohkura, H. Polo boxes form a singlefunctional domain that mediates interactions withmultiple proteins in fission yeast polo kinase. J. CellSci. 116, 1377-1387 (2003).
34. Elia, A. E., Cantley, L. C. & Yaffe, M. B. Proteomicscreen finds pSer/pThr-binding domain localizing Plk1to mitotic substrates. Science 299, 1228-1231(2003). This excellent paper identifies the polo-boxdomain of Plk1 as a specific phosphoserineor phosphothreonine binding domain.
35. van de Weerdt, B. C. et al. Polo-box domains confertarget specificity to the polo-like kinase family. Biochim. Biophys. Acta 1783, 1015-1022 (2008).
36. Neef, R. et al. Phosphorylation of mitotic kinesin-likeprotein 2 by polo-like kinase 1 is required forcytokinesis. J. Cell Biol. 162, 863-875 (2003).
37. Kang, Y. H. et al. Self-regulated Plk1 recruitment tokinetochores by the Plk1-PBIP1 interaction is criticalfor proper chromosome segregation. Mol. Cell 24,409-422 (2006).
38. Neef, R. et al. Choice of Plk1 docking partnersduring mitosis and cytokinesis is controlled by theactivation state of Cdk1. Nat. Cell Biol. 9, 436-444(2007).
39. Jang, Y. J., Lin, C. Y., Ma, S. & Erikson, R. L. Functional studies on the role of the C-terminaldomain of mammalian polo-like kinase. Proc. NatlAcad. Sci. USA 99, 1984-1989 (2002).
40. Mundt, K. E., Golsteyn, R. M., Lane, H. A. &Nigg, E. A. On the regulation and function of humanpolo-like kinase 1 (PLK1): effects of overexpressionon cell cycle progression. Biochem. Biophys. Res. Commun. 239, 377-385 (1997).
41. Elia, A. E. et al. The molecular basis forphosphodependent substrate targeting andregulation of Plks by the polo-box domain. Cell115, 83-95 (2003).
42. Golsteyn, R. M., Mundt, K. E., Fry, A. M. & Nigg, E. A. Cell cycle regulation of the activity and subcellularlocalization of Plk1, a human protein kinaseimplicated in mitotic spindle function. J. Cell Biol. 129, 1617-1628 (1995).
43. Jang, Y. J., Ma, S., Terada, Y. & Erikson, R. L. Phosphorylation of threonine 210 and the role ofserine 137 in the regulation of mammalian polo-likekinase. J. Biol. Chem. 277, 44115-44120 (2002).
44. Kelm, O., Wind, M., Lehmann, W. D. & Nigg, E. A. Cell cycle-regulated phosphorylation of theXenopus polo-like kinase Plx1. J. Biol. Chem. 277,25247-25256 (2002).
45. Daub, H. et al. Kinase-selective enrichment enablesquantitative phosphoproteomics of the kinome acrossthe cell cycle. Mol. Cell 31, 438-448 (2008).
46. Qian, Y. W., Erikson, E. & Maller, J. L. Purification andcloning of a protein kinase that phosphorylates andactivates the polo-like kinase Plx1. Science 282,1701-1704 (1998).
47. Ellinger-Ziegelbauer, H. et al. Ste20-like kinase (SLK),a regulatory kinase for polo-like kinase (Plk) during theG2/M transition in somatic cells. Genes Cells 5,491-498 (2000).
48. Chan, E. H., Santamaria, A., Sillje, H. H. & Nigg, E. A. Plk1 regulates mitotic Aurora A function throughβTrCP-dependent degradation of hBora. Chromosoma117, 457-469 (2008).
49. Seki, A., Coppinger, J. A., Jang, C. Y., Yates, J. R. &Fang, G. Bora and the kinase Aurora A cooperativelyactivate the kinase Plk1 and control mitotic entry. Science 320, 1655-1658 (2008).
50. Macurek, L. et al. Polo-like kinase-1 is activated byAurora A to promote checkpoint recovery. Nature455, 119-123 (2008). References 48-50 establish the role of bora forthe activation of PLK1 by Aurora A.
51. Laoukili, J. et al. FoxM1 is required for execution ofthe mitotic programme and chromosome stability. Nat. Cell Biol. 7, 126-136 (2005).
52. Major, M. L., Lepe, R. & Costa, R. H. Forkhead boxM1B transcriptional activity requires binding of Cdkcyclincomplexes for phosphorylation- dependentrecruitment of p300/CBP coactivators. Mol. Cell Biol. 24, 2649-2661 (2004).
53. Wang, I. C. et al. Forkhead box M1 regulates thetranscriptional network of genes essential for mitoticprogression and genes encoding the SCF (Skp2-Cks1)ubiquitin ligase. Mol. Cell Biol. 25, 10875-10894(2005).
54. Fu, Z. et al. Plk1-dependent phosphorylation ofFoxM1 regulates a transcriptional programmerequired for mitotic progression. Nat. Cell Biol. 10,1076-1082 (2008).
55. Martin, B. T. & Strebhardt, K. Polo-like kinase 1:target and regulator of transcriptional control. Cell Cycle 5, 2881-2885 (2006).
56. Ando, K. et al. Polo-like kinase 1 (Plk1) inhibits p53function by physical interaction and phosphorylation. J. Biol. Chem. 279, 25549-25561 (2004).
57. Whibley, C., Pharoah, P. D. & Hollstein, M. p53polymorphisms: cancer implications. Nature Rev. Cancer 9, 95-107 (2009).
58. Vazquez, A., Bond, E. E., Levine, A. J. & Bond, G. L. The genetics of the p53 pathway, apoptosis andcancer therapy. Nature Rev. Drug Discov. 7, 979-987(2008).
59. Liu, X. & Erikson, R. L. Polo-like kinase (Plk)1depletion induces apoptosis in cancer cells. Proc. NatlAcad. Sci. USA 100, 5789-5794 (2003).
60. Liu, X., Lei, M. & Erikson, R. L. Normal cells, but notcancer cells, survive severe Plk1 depletion. Mol. CellBiol. 26, 2093-2108 (2006).
61. Guan, R. et al. Small interfering RNA-mediatedpolo-like kinase 1 depletion preferentially reduces thesurvival of p53-defective, oncogenic transformed cellsand inhibits tumor growth in animals. Cancer Res. 65,2698-2704 (2005).
62. Yang, X. et al. Plk1-mediated phosphorylation oftopors regulates p53 stability. J. Biol. Chem. 284,18588-18592 (2009).
63. Weger, S., Hammer, E. & Heilbronn, R. Topors acts asa SUMO-1 E3 ligase for p53 in vitro and in vivo. FEBSLett. 579, 5007-5012 (2005).
64. Rajendra, R. et al. Topors functions as an E3 ubiquitinligase with specific E2 enzymes and ubiquitinates p53. J. Biol. Chem. 279, 36440-36444 (2004).
65. Momand, J., Wu, H. H. & Dasgupta, G. MDM2-masterregulator of the p53 tumor suppressor protein. Gene242, 15-29 (2000).
66. Kreis, N. N. et al. Long-term downregulation of pololikekinase 1 increases the cyclin-dependent kinaseinhibitor p21WAF1/CIP1. Cell Cycle 8, 460-472 (2009).
67. Koida, N. et al. Inhibitory role of Plk1 in the regulationof p73-dependent apoptosis through physicalinteraction and phosphorylation. J. Biol. Chem. 283,8555-8563 (2008).
68. Soond, S. M. et al. p73-mediated transcriptionalactivity is negatively regulated by polo-like kinase 1. Cell Cycle 7, 1214-1223 (2008).
69. Kaghad, M. et al. Monoallelically expressed generelated to p53 at 1p36, a region frequently deleted inneuroblastoma and other human cancers. Cell 90,809-819 (1997).
70. Sur, S. et al. A panel of isogenic human cancer cellssuggests a therapeutic approach for cancers withinactivated p53. Proc. Natl Acad. Sci. USA 106,3964-3969 (2009).
71. zur Hausen, H. Papillomaviruses and cancer: frombasic studies to clinical application. Nature Rev. Cancer 2:342-350, 2002.
72. Patel, D., Incassati, A., Wang, N. & McCance, D. J. Human papillomavirus type 16 E6 and E7 causepolyploidy in human keratinocytes and up-regulationof G2-M-phase proteins. Cancer Res. 64, 1299-1306(2004).
73. Incassati, A., Patel, D. & McCance, D. J. Induction oftetraploidy through loss of p53 and upregulation ofPlk1 by human papillomavirus type-16 E6. Oncogene25, 2444-2451 (2006).
74. Meraldi, P., Honda, R. & Nigg, E. A. Aurora-Aoverexpression reveals tetraploidization as a majorroute to centrosome amplification in p53-/-cells. EMBO J. 21, 483-492 (2002).
75. Lin, H. R., Ting, N. S., Qin, J. & Lee, W. H. M phasespecificphosphorylation of BRCA2 by polo-like kinase 1correlates with the dissociation of the BRCA2-P/CAFcomplex. J. Biol. Chem. 278, 35979-35987 (2003).
76. Lee, M., Daniels, M. J. & Venkitaraman, A. R. Phosphorylation of BRCA2 by the polo-like kinasePlk1 is regulated by DNA damage and mitoticprogression. Oncogene 23, 865-872 (2004).
77. Tsvetkov, L., Xu, X., Li, J. & Stern, D. F. Polo-like kinase1 and Chk2 interact and co-localize to centrosomesand the midbody. J. Biol. Chem. 278, 8468-8475(2003).
78. van Vugt, M. A., Smits, V. A., Klompmaker, R. &Medema, R. H. Inhibition of polo-like kinase-1 by DNAdamage occurs in an ATM-or ATR-dependent fashion. J. Biol. Chem. 276, 41656-41660 (2001).
79. Ree, A. H., Bratland, A., Nome, R. V., Stokke, T. &Fodstad, O. Repression of mRNA for the PLK cell cyclegene after DNA damage requires BRCA1. Oncogene22, 8952-8955 (2003).
80. Tang, J., Erikson, R. L. & Liu, X. Checkpoint kinase 1(Chk1) is required for mitotic progression throughnegative regulation of polo-like kinase 1 (Plk1). Proc. Natl Acad. Sci USA 103, 11964-11969 (2006).
81. Smith, M. R. et al. Malignant transformation ofmammalian cells initiated by constitutive expression ofthe polo-like kinase. Biochem. Biophys. Res. Commun. 234, 397-405 (1997).
82. Smits, V. A. et al. Polo-like kinase-1 is a target ofthe DNA damage checkpoint. Nature Cell Biol. 2,672-676 (2000). This paper reports that PLK1 is an importanttarget of the DNA damage checkpoint.
83. Syljuasen, R. G., Jensen, S., Bartek, J. & Lukas, J. Adaptation to the ionizing radiation-induced G2checkpoint occurs in human cells and depends oncheckpoint kinase 1 and polo-like kinase 1 kinases. Cancer Res. 66, 10253-10257 (2006).
84. Yamaguchi, T. et al. Phosphorylation by Cdk1 inducesPlk1-mediated vimentin phosphorylation duringmitosis. J. Cell Biol. 171, 431-436 (2005).
85. Rizki, A., Mott, J. D. & Bissell, M. J. Polo-like kinase 1is involved in invasion through extracellular matrix. Cancer Res. 67, 11106-11110 (2007).
86. Eckerdt, F., Yuan, J. & Strebhardt, K. Polo-like kinasesand oncogenesis. Oncogene 24, 267-276 (2005).
87. Takai, N., Hamanaka, R., Yoshimatsu, J. & Miyakawa, I. Polo-like kinases (Plks) and cancer. Oncogene 24,287-291 (2005).
88. Wolf, G. et al. Prognostic significance of polo-likekinase (PLK) expression in non-small cell lung cancer. Oncogene 14, 543-549 (1997).
89. Knecht, R. et al. Prognostic significance of polo-likekinase (PLK) expression in squamous cell carcinomasof the head and neck. Cancer Res. 59, 2794-2797(1999). References 88 and 89 both describe for the firsttime the clinical relevance of PLK1 overexpressionfor patients with tumours.
90. Salvatore, G. et al. A cell proliferation andchromosomal instability signature in anaplasticthyroid carcinoma. Cancer Res. 67, 10148-10158(2007).
91. Liu, L., Zhang, M. & Zou, P. Expression of PLK1 andsurvivin in diffuse large B-cell lymphoma. Leuk. Lymphoma 48, 2179-2183 (2007).
92. Yamamoto, Y. et al. Overexpression of polo-likekinase 1 (PLK1) and chromosomal instability inbladder cancer. Oncology 70, 231-237 (2006).
93. Liu, L., Zhang, M. & Zou, P. Polo-like kinase 1 as anew target for non-Hodgkin's lymphoma treatment. Oncology 74, 96-103 (2008).
94. Kanaji, S. et al. Expression of polo-like kinase 1 (PLK1)protein predicts the survival of patients with gastriccarcinoma. Oncology 70, 126-133 (2006).
95. Jang, Y. J., Kim, Y. S. & Kim, W. H. Oncogenic effectof polo-like kinase 1 expression in human gastriccarcinomas. Int. J. Oncol. 29, 589-594 (2006).
96. Weichert, W. et al. Expression patterns of polo-likekinase 1 in human gastric cancer. Cancer Sci. 97,271-276 (2006).
97. Simmons, D. L., Neel, B. G., Stevens, R., Evett, G. & Erikson, R. L. Identification of an early-growthresponsegene encoding a novel putative proteinkinase. Mol. Cell Biol. 12, 4164-4169 (1992).
98. Ma, S., Liu, M. A., Yuan, Y. L. & Erikson, R. L. Theserum-inducible protein kinase Snk is a G1 phasepolo-like kinase that is inhibited by the calcium-andintegrin-binding protein CIB. Mol. Cancer Res. 1,376-384 (2003).
99. Anger, M. et al. Cell cycle dependent expressionof Plk1 in synchronized porcine fetal fibroblasts. Mol. Reprod. Dev. 65, 245-253 (2003).
100. Warnke, S. et al. Polo-like kinase-2 is required forcentriole duplication in mammalian cells. Curr. Biol. 14, 1200-1207 (2004).
101. Cizmecioglu, O., Warnke, S., Arnold, M., Duensing, S. & Hoffmann, I. Plk2 regulated centriole duplication isdependent on its localization to the centrioles and afunctional polo-box domain. Cell Cycle 7, 3548-3555(2008).
102. Ma, S., Charron, J. & Erikson, R. L. Role of Plk2 (Snk)in mouse development and cell proliferation. Mol. CellBiol. 23, 6936-6943 (2003).
103. Habedanck, R., Stierhof, Y. D., Wilkinson, C. J. &Nigg, E. A. The polo kinase Plk4 functions in centrioleduplication. Nature Cell Biol. 7, 1140-1146 (2005).
104. Kauselmann, G. et al. The polo-like protein kinasesFnk and Snk associate with a Ca2+-and integrinbindingprotein and are regulated dynamically withsynaptic plasticity. EMBO J. 18, 5528-5539 (1999).
105. Burns, T. F., Fei, P., Scata, K. A., Dicker, D. T. &El-Deiry, W. S. Silencing of the novel p53 target geneSnk/Plk2 leads to mitotic catastrophe in paclitaxel(taxol)-exposed cells. Mol. Cell Biol. 23, 5556-5571(2003).
106. Tovar, C. et al. Small-molecule MDM2 antagonistsreveal aberrant p53 signaling in cancer: implicationsfor therapy. Proc. Natl Acad. Sci. USA 103,1888-1893 (2006).
107. Khan, S. H. & Wahl, G. M. p53 and pRb preventrereplication in response to microtubule inhibitors bymediating a reversible G1 arrest. Cancer Res. 58,396-401 (1998).
108. Lanni, J. S. & Jacks, T. Characterization of the p53-dependent postmitotic checkpoint following spindledisruption. Mol. Cell Biol. 18, 1055-1064 (1998).
109. Van den Berghe, H. & Michaux, L. 5q, twenty-fiveyears later: a synopsis. Cancer Genet. Cytogenet. 94, 1-7 (1997).
110. Nimer, S. D. & Golde, D. W. The 5q-abnormality. Blood 70, 1705-1712 (1987).
111. Syed, N. et al. Transcriptional silencing of polo-likekinase 2 (SNK/PLK2) is a frequent event in B-cellmalignancies. Blood 107, 250-256 (2006).
112. Li, Z. et al. Distinct microRNA expression profiles inacute myeloid leukemia with common translocations. Proc. Natl Acad. Sci. USA 105, 15535-15540(2008).
113. Esquela-Kerscher, A. & Slack, F. J. Oncomirs-microRNAs with a role in cancer. Nature Rev. Cancer6, 259-269 (2006).
114. Donohue, P. J., Alberts, G. F., Guo, Y. & Winkles, J. A. Identification by targeted differential display of animmediate early gene encoding a putative serine/threonine kinase. J. Biol. Chem. 270, 10351-10357(1995).
115. Li, B. et al. Prk, a cytokine-inducible human proteinserine/threonine kinase whose expression appears tobe down-regulated in lung carcinomas. J. Biol. Chem. 271, 19402-19408 (1996).
116. Holtrich, U. et al. Adhesion induced expression of theserine/threonine kinase Fnk in human macrophages. Oncogene 19, 4832-4839 (2000).
117. Ouyang, B. et al. Human Prk is a conserved proteinserine/threonine kinase involved in regulatingM phase functions. J. Biol. Chem. 272,28646-28651 (1997).
118. Chase, D. et al. Expression and phosphorylation offibroblast-growth- factor-inducible kinase (Fnk) duringcell-cycle progression. Biochem. J. 333 (Pt 3),655-660 (1998).
119. Bahassiel, M. et al. Mammalian polo-like kinase 3(Plk3) is a multifunctional protein involved in stressresponse pathways. Oncogene 21, 6633-6640(2002).
120. Zimmerman, W. C. & Erikson, R. L. Polo-like kinase 3is required for entry into S phase. Proc. Natl Acad. Sci. USA 104, 1847-1852 (2007).
121. Wang, Q. et al. Cell cycle arrest and apoptosis inducedby human polo-like kinase 3 is mediated throughperturbation of microtubule integrity. Mol. Cell Biol. 22, 3450-3459 (2002).
122. Jiang, N., Wang, X., Jhanwar-Uniyal, M.,Darzynkiewicz, Z. & Dai, W. Polo box domain ofPlk3 functions as a centrosome localization signal,overexpression of which causes mitotic arrest,cytokinesis defects, and apoptosis. J. Biol. Chem. 281, 10577-10582 (2006).
123. Yang, F. et al. Identification of a novel mitoticphosphorylation motif associated with proteinlocalization to the mitotic apparatus. J. Cell Sci. 120, 4060-4070 (2007).
124. Ruan, Q. et al. Polo-like kinase 3 is golgi localized andinvolved in regulating golgi fragmentation during thecell cycle. Exp. Cell Res. 294, 51-59 (2004).
125. Lopez-Sanchez, I., Sanz-Garcia, M. & Lazo, P. A. Plk3interacts with and specifically phosphorylates VRK1in Ser342, a downstream target in a pathway thatinduces golgi fragmentation. Mol. Cell Biol. 29,1189-1201 (2009).
126. Sutterlin, C., Hsu, P., Mallabiabarrena, A. & Malhotra, V. Fragmentation and dispersal of the pericentriolargolgi complex is required for entry into mitosis inmammalian cells. Cell 109, 359-369 (2002).
127. Conn, C. W., Hennigan, R. F., Dai, W., Sanchez, Y. &Stambrook, P. J. Incomplete cytokinesis and inductionof apoptosis by overexpression of the mammalianpolo-like kinase, Plk3. Cancer Res. 60, 6826-6831(2000).
128. Zhou, T. et al. Profiles of global gene expression inionizing-radiation- damaged human diploid fibroblastsreveal synchronization behind the G1 checkpoint in aG0-like state of quiescence. Environ. Health Perspect. 114, 553-559 (2006).
129. Kis, E. et al. Microarray analysis of radiation responsegenes in primary human fibroblasts. Int. J. Radiat. Oncol. Biol. Phys. 66, 1506-1514 (2006).
130. Staib, F. et al. The p53 tumor suppressor networkis a key responder to microenvironmental componentsof chronic inflammatory stress. Cancer Res. 65,10255-10264 (2005).
131. Han, E. S. et al. The in vivo gene expression signatureof oxidative stress. Physiol. Genomics 34, 112-126(2008).
132. Yang, Y. et al. Polo-like kinase 3 functions as a tumorsuppressor and is a negative regulator of hypoxiainduciblefactor-1α under hypoxic conditions. CancerRes. 68, 4077-4085 (2008).
133. Wang, L., Gao, J., Dai, W. & Lu, L. Activation ofpolo-like kinase 3 by hypoxic stresses. J. Biol. Chem. 283, 25928-25935 (2008).
134. Dai, W. et al. PRK, a cell cycle gene localized to 8p21,is downregulated in head and neck cancer. GenesChromosomes. Cancer 27, 332-336 (2000).
135. Weichert, W. et al. Polo-like kinase isoforms in breastcancer: expression patterns and prognosticimplications. Virchows Arch. 446, 442-450 (2005).
136. Weichert, W. et al. Polo-like kinase isoformexpression is a prognostic factor in ovariancarcinoma. Br. J. Cancer 90, 815-821 (2004).
137. Fode, C., Motro, B., Yousefi, S., Heffernan, M. &Dennis, J. W. Sak, a murine protein-serine/threoninekinase that is related to the Drosophila polo kinaseand involved in cell proliferation. Proc. Natl Acad. Sci. USA 91, 6388-6392 (1994).
138. Fode, C., Binkert, C. & Dennis, J. W. Constitutiveexpression of murine Sak-a suppresses cell growthand induces multinucleation. Mol. Cell Biol. 16,4665-4672 (1996).
139. Hudson, J. W. et al. Late mitotic failure in mice lackingSak, a polo-like kinase. Curr. Biol. 11, 441-446(2001).
140. Bettencourt-Dias, M. et al. SAK/PLK4 is requiredfor centriole duplication and flagella development. Curr. Biol. 15, 2199-2207 (2005).
141. Li, J. et al. SAK, a new polo-like kinase, istranscriptionally repressed by p53 and inducesapoptosis upon RNAi silencing. Neoplasia. 7,312-323 (2005).
142. Deloukas, P. et al. A physical map of 30,000 humangenes. Science 282, 744-746 (1998).
143. Hammond, C., Jeffers, L., Carr, B. I. & Simon, D. Multiple genetic alterations, 4q28, a new suppressorregion, and potential gender differences in humanhepatocellular carcinoma. Hepatology 29,1479-1485 (1999).
144. Hudson, J. W., Chen, L., Fode, C., Binkert, C. &Dennis, J. W. Sak kinase gene structure andtranscriptional regulation. Gene 241, 65-73 (2000).
145. Macmillan, J. C., Hudson, J. W., Bull., S., Dennis, J. W. & Swallow, C. J. Comparative expression of themitotic regulators SAK and PLK in colorectal cancer. Ann. Surg. Oncol. 8, 729-740 (2001).
146. Keen, N. & Taylor, S. Aurora-kinase inhibitors asanticancer agents. Nature Rev. Cancer 4, 927-936(2004).
147. Pérez de Castro, I., de Cárcer, G., Montoya, G. &Malumbres, M. Emerging cancer therapeuticopportunities by inhibiting mitotic kinases. Curr. Opin. Pharmacol. 8, 375-383 (2008).
148. McInnes, C. Progress in the evaluation of CDKinhibitors as anti-tumor agents. Drug Discov. Today13, 875-881 (2008).
149. Lapenna, S. & Giordano, A. Cell cycle kinases astherapeutic targets for cancer. Nature Rev. DrugDiscov. 8, 547-566 (2009).
150. Yuan, J., Kramer, A., Eckerdt, F., Kaufmann, M. &Strebhardt, K. Efficient internalization of the polo-boxof polo-like kinase 1 fused to an antennapedia peptideresults in inhibition of cancer cell proliferation. CancerRes. 62, 4186-4190 (2002).
151. Spankuch, B. et al. Cancer inhibition in nude miceafter systemic application of U6 promoter-driven shorthairpin RNAs against PLK1. J. Natl. Cancer Inst. 96,862-872 (2004).
152. Matthess, Y. et al. Conditional inhibition of cancer cellproliferation by tetracycline-responsive, H1 promoterdrivensilencing of PLK1. Oncogene 24, 2973-2980(2005).
153. Kappel, S., Matthess, Y., Zimmer, B., Kaufmann, M. & Strebhardt, K. Tumor inhibition by genomicallyintegrated inducible RNAi-cassettes. Nucleic AcidsRes. 34, 4527-4536 (2006).
154. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complementof the human genome. Science 298, 1912-1934(2002).
155. Goldstein, D. M., Gray, N. S. & Zarrinkar, P. P. High-throughput kinase profiling as a platform fordrug discovery. Nature Rev. Drug Discov. 7, 391-397(2008).
156. Johnson, E. F., Stewart, K. D., Woods, K. W.,Giranda, V. L. & Luo, Y. Pharmacological andfunctional comparison of the polo-like kinase family:insight into inhibitor and substrate specificity. Biochemistry 46, 9551-9563 (2007).
157. Kothe, M. et al. Structure of the catalytic domainof human polo-like kinase 1. Biochemistry 46,5960-5971 (2007).
158. Steegmaier, M. et al. BI 2536, a potent and selectiveinhibitor of polo-like kinase 1, inhibits tumor growthin vivo. Curr. Biol. 17, 316-322 (2007).
159. Kothe, M. et al. Selectivity-determining residues inPlk1. Chem. Biol. Drug Des. 70, 540-546 (2007).
160. Wang, H. Y. et al. Pharmacophore modeling and virtualscreening for designing potential PLK1 inhibitors. Bioorg. Med. Chem. Lett. 18, 4972-4977 (2008).
161. McInnes, C. et al. Inhibitors of polo-like kinase revealroles in spindle-pole maintenance. Nature Chem. Biol. 2, 608-617 (2006).
162. Peters, U., Cherian, J., Kim, J. H., Kwok, B. H. &Kapoor, T. M. Probing cell-division phenotype spaceand polo-like kinase function using small molecules. Nature Chem. Biol. 2, 618-626 (2006). References 161 and 162 are both excellentpapers that describe the effects of novelsmall-molecule inhibitors targeting the kinasedomain of PLK1.
163. Santamaria, A. et al. Use of the novel Plk1 inhibitorZK-thiazolidinone to elucidate functions of Plk1 inearly and late stages of mitosis. Mol. Biol. Cell 18,4024-4036 (2007).
164. Lansing, T. J. et al. In vitro biological activity of anovel small-molecule inhibitor of polo-like kinase 1. Mol. Cancer Ther. 6, 450-459 (2007).
165. Baumann, C., Korner, R., Hofmann, K. & Nigg, E. A. PICH, a centromere-associated SNF2 family ATPase,is regulated by Plk1 and required for the spindlecheckpoint. Cell 128, 101-114 (2007).
166. Sato, Y. et al. Imidazopyridine derivatives as potentand selective polo-like kinase (PLK) inhibitors. Bioorg. Med. Chem. Lett. 19, 4673-4678 (2009).
167. Mahajan, S. et al. Rational design and synthesis of anovel anti-leukemic agent targeting Bruton's tyrosinekinase (BTK), LFM-A13 [α-cyano-β- hydroxy-β-methyl-N-(2,5-dibromophenyl)propenamide]. J. Biol. Chem. 274, 9587-9599 (1999).
168. Uckun, F. M. et al. Anti-breast cancer activity ofLFM-A13, a potent inhibitor of polo-like kinase (PLK). Bioorg. Med. Chem. 15, 800-814 (2007).
169. Uckun, F. M. Chemosensitizing anti-cancer activityof LFM-A13, a leflunomide metabolite analogtargeting polo-like kinases. Cell Cycle 6, 3021-3026(2007).
170. Reindl, W., Yuan, J., Kramer, A., Strebhardt, K. &Berg, T. Inhibition of polo-like kinase 1 by blockingpolo-box domain-dependent protein- proteininteractions. Chem. Biol. 15, 459-466 (2008). This paper describes the inhibition of thepolo-box domain function by a small-moleculeinhibitor.
171. Reindl, W., Strebhardt, K. & Berg, T. A highthroughputassay based on fluorescencepolarization for inhibitors of the polo-box domain ofpolo-like kinase 1. Anal. Biochem. 383, 205-209(2008).
172. Hanisch, A., Wehner, A., Nigg, E. A. & Sillje, H. H. Different Plk1 functions show distinct dependencies onpolo-box domain-mediated targeting. Mol. Biol. Cell17, 448-459 (2006).
173. Gali-Muhtasib, H., Roessner, A. & Schneider-Stock, R. Thymoquinone: a promising anti-cancer drug fromnatural sources. Int. J. Biochem. Cell Biol. 38,1249-1253 (2006).
174. Kaseb, A. O. et al. Androgen receptor and E2F-1targeted thymoquinone therapy for hormonerefractoryprostate cancer. Cancer Res. 67,7782-7788 (2007).
175. Reindl, W., Yuan, J., Kramer, A., Strebhardt, K. &Berg, T. A pan-specific inhibitor of the polo-boxdomains of polo-like kinases arrests cancer cells inmitosis. Chembiochem. 10, 1145-1148 (2009).
176. Watanabe, N. et al. Deficiency in chromosomecongression by the inhibition of Plk1 polo boxdomain-dependent recognition. J. Biol. Chem. 284,2344-2353 (2009).
177. Abou-Karam, M. & Shier, W. T. Inhibition of oncogeneproduct enzyme activity as an approach to cancerchemoprevention. Tyrosine-specific protein kinaseinhibition by purpurogallin from Quercus sp. nutgall. Phytother. Res. 13, 337-340 (1999).
178. Farnet, C. M. et al. Human immunodeficiency virustype 1 cDNA integration: new aromatic hydroxylatedinhibitors and studies of the inhibition mechanism. Antimicrob. Agents Chemother. 42, 2245-2253(1998).
179. Inamori, Y. et al. Biological activity of purpurogallin. Biosci. Biotechnol. Biochem. 61, 890-892 (1997).
180. Jackson, J. R., Patrick, D. R., Dar, M. M. & Huang,P. S. Targeted anti-mitotic therapies: can we improveon tubulin agents? Nature Rev. Cancer 7, 107-117(2007).
181. Gumireddy, K. et al. ON01910, a non-ATP-competitivesmall molecule inhibitor of Plk1, is a potent anticanceragent. Cancer Cell 7, 275-286 (2005).
182. Lenart, P. et al. The small-molecule inhibitor BI 2536reveals novel insights into mitotic roles of polo-likekinase 1. Curr. Biol. 17, 304-315 (2007).
183. Jimeno, A. et al. Phase I study of ON 01910. Na, anovel modulator of the polo-like kinase 1 pathway,in adult patients with solid tumors. J. Clin. Oncol. 26, 5504-5510 (2008).
184. Jimeno, A. et al. Evaluation of the novel mitoticmodulator ON 01910. Na in pancreatic cancer andpreclinical development of an ex vivo predictive assay. Oncogene 28, 610-618 (2009).
185. Weinstein, J. et al. Phase I study of ON 01910. Na,a novel polo-like kinase 1 pathway modulator,administered as a weekly 24-hour continuous infusionin patients with advanced cancer. J. Clin. Oncol. 26,(2008).
186. Ghalib,M. H. et al. ON01910. Na, a novel polo-likekinase pathway modulator as a treatment for patientswith advanced cancer. AACR meeting website [online],http://www. aacrmeetingabstracts. org/cgi/gcaallch=&SEARCHID= 1&AUTHOR1=Ghalib&FIRSTINDEX=0&hits=10&RESULTFORMAT=&gca= aacrmtg%3B2008%2F1-Annual-Meeting%2F5652 (2008).
187. Ohnuma, T. et al. Phase I study of ON 01910. Na by3-day continuous infusion (CI) in patients (pts) withadvanced cancer. J. Clin. Oncol. 24 (Suppl. 18),13137 (2006).
188. Chapman, C. M., Perez-Galan, P. & Wiestner, A. ON 01910. Na, a novel clinical grade PLK-1 inhibitor,selectively induces apoptosis in human B-cell chroniclymphocytic leukemia (B-CLL). Onconova website[online], http://www. onconova. com/pdfs/publications/AACR2009%20Abstracts. pdf (2009).
189. Tanaka, H. et al. HMN-176, an active metabolite ofthe synthetic antitumor agent HMN-214, restoreschemosensitivity to multidrug-resistant cells bytargeting the transcription factor NF-Y. Cancer Res. 63, 6942-6947 (2003).
190. Garland, L. L., Taylor, C., Pilkington, D. L., Cohen, J. L. & Von Hoff, D. D. A phase I pharmacokinetic study ofHMN-214, a novel oral stilbene derivative with pololikekinase-1-interacting properties, in patients withadvanced solid tumors. Clin. Cancer Res. 12,5182-5189 (2006).
191. Von Hoff, D. D., Taylor, C., Rubin, S., Cohen, J. &Garland, L. A phase I and pharmacokinetic study ofHMN-214, a novel oral polo-like kinase inhibitor, inpatients with advanced solid tumors. J. Clin. Oncol. 22 (Suppl. 14), 3034 (2004).
192. Patnaik, A. et al. HMN-214, a novel oralantimicrotubular agent and inhibitor of polo-like-andcyclin-dependent kinases: clinical, pharmacokinetic(PK) and pharmacodynamic (PD) relationshipsobserved in a phase I trial of a daily x 5 scheduleevery 28 days. Proc. Am. Soc. Clin. Oncol. 22, 514(2003).
193. Emmitte, K. A. et al. Discovery of thiophene inhibitorsof polo-like kinase. Bioorg. Med. Chem. Lett. 19,1018-1021 (2009).
194. Emmitte, K. A. et al. Design of potent thiopheneinhibitors of polo-like kinase 1 with improved solubilityand reduced protein binding. Bioorg. Med. Chem. Lett. 19, 1694-1697 (2009).
195. Erskine, S. et al. Biochemical characterization ofGSK461364: a novel, potent, and selective inhibitorof polo-like kinase 1 (Plk1). Proc. Annu. Meet. Am. Assoc. Cancer Res. Abstr. 3257 (2007).
196. Laquerre, S. et al. A potent and selective polo-likekinase 1 (Plk1) inhibitor (GSK461364) induces cellcycle arrest and growth inhibition of cancer cell. AACR meeting website [online], http://www. aacrmeetingabstracts. org/cgi/gcaallch=&SEARCHID=1&AUTHOR1=Laquerre&FIRSTINDEX=0&hits= 10&RESULTFORMAT=&gca=aacrmtg%3B2007%2F1-Annual-Meeting%2F5389 (2007).
197. Erskine, S. et al. Biochemical characterization ofGSK461364: a novel, potent, and selective inhibitorof polo-like kinase-1 (Plk1). AACR meeting website[online], http://www. aacrmeetingabstracts. org/cgi/gcaallch= &SEARCHID=1&AUTHOR1=Erskine&FULLTEXT=Plk1&FIRSTINDEX=0&hits= 10&RESULTFORMAT=&gca=aacrmtg%3B2007%2F1-Annual-Meeting%2F3257 (2007).
198. Sutton, D. et al. Efficacy of GSK461364, a selectivePlk1 inhibitor, in human tumor xenograft models. AACR meeting website [online], http://www. aacrmeetingabstracts. org/cgi/gcaallch=&SEARCHID=1&AUTHOR1= Sutton&FULLTEXT=GSK461364&FIRSTINDEX=0&hits=10&RESULTFORMAT= &gca=aacrmtg%3B2007%2F1-Annual-Meeting%2F5388 (2007).
199. Ikezoe, T. et al. A novel treatment strategy targetingpolo-like kinase 1 in hematological malignancies. Leukemia 23, 1564-1576 (2009).
200. Didier, C., Cavelier, C., Quaranta, M., Demur, C. &Ducommun, B. Evaluation of polo-like kinase 1inhibition on the G2/M checkpoint in acute myelocyticleukaemia. Eur. J. Pharmacol. 591, 102-105 (2008).
201. Olmos, D. et al. Phase I first-in-human study of thepolo-like kinase-1 selective inhibitor, GSK461364,in patients with advanced solid tumors. J. Clin. Oncol. 27 (Suppl. 15) 3536 (2009).
202. Beria, I. et al. Identification of 4, 5-Dihydro-1Hpyrazolo[4,3-h] quinazoline derivatives as a new classof orally and selective polo-like kinase 1 inhibitors. J. Med. Chem. 53 (Suppl. 9), 3532-3551(2010).
203. Valsasina, B. et al. Pyrazoloquinazolines: from anunselective hit to a potent Plk1-specific inhibitor. AACR website [online], http://www. abstractsonline. com/viewer/viewAbstractPrintFriendly. aspCKey={716D6BF1-9F4C- 475D-BC07-49C954251C47}&SKey={8479D63F-A150-4BA5-A046-74836CFE9ECB} &MKey={D007B270-E8F6-492D-803B-7582CE7A0988}&AKey={728BCE9C-121B-46B9- A8EE-DC51FDFC6C15} (2009).
204. Mross, K. et al. Phase I dose escalation andpharmacokinetic study of BI 2536, a novel polo-likekinase 1 inhibitor, in patients with advanced solidtumors. J. Clin. Oncol. 26, 5511-5517 (2008).
205. Hofheinz, R. et al. A phase I repeated dose escalationstudy of the polo-like kinase 1 inhibitor BI 2536 inpatients with advanced solid tumors. J. Clin. Oncol. 24 (Suppl 18), 2038 (2006).
206. Ellis, P. M. et al. A phase I dose escalation trial of BI2536, a novel Plk1 inhibitor, with standard dosepemetrexed in previously treated advanced ormetastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. 26, 8115 (2008).
207. von Pawel, J. et al. Randomized phase II trial of twodosing schedules of BI 2536, a novel Plk-1 inhibitor,in patients with relapsed advanced or metastatic nonsmall-cell lung cancer (NSCLC). J. Clin. Oncol. 26,8030 (2008).
208. Pandha, H. S. et al. An open label phase II trial ofBI 2536, a novel Plk1 inhibitor, in patients withmetastatic hormone refractory prostate cancer(HRPC). J. Clin. Oncol. 26, 14547 (2008).
209. Mross, K. et al. A randomized phase II trial of thenovel polo-like kinase 1 inhibitor BI 2536 inchemonaïve patients with unresectable advancedpancreatic cancer: a study in cooperation with theCESAR network of investigators. Ann. Oncol. 19(Suppl. 8), 493P (2008).
210. Rudolph, D. et al. BI 6727, a polo-like kinase inhibitorwith improved pharmacokinetic profile and broadantitumor activity. Clin. Cancer Res. 15, 3094-3102(2009).
211. Schöffski, P. et al. A phase I single dose escalationstudy of the novel polo-like kinase I inhibitor BI 6727in patients with advanced solid tumors. Eur. J. Cancer6 (Suppl.), 14-15 (2008).
212. Luo, J. et al. A genome-wide RNAi screen identifiesmultiple synthetic lethal interactions with the Rasoncogene. Cell 137, 835-848 (2009).
213. Park, J. E. et al. Direct quantification of polo-likekinase 1 activity in cells and tissues using a highlysensitive and specific ELISA assay. Proc. Natl Acad. Sci. USA 106, 1725-1730 (2009).
214. Judge, A. D. et al. Confirming the RNAi-mediatedmechanism of action of siRNA-based cancertherapeutics in mice. J. Clin. Invest. 119, 661-673(2009).
215. Spankuch, B. et al. Downregulation of Plk1 expressionby receptor-mediated uptake of antisenseoligonucleotide-loaded nanoparticles. Neoplasia. 10,223-234 (2008).
216. Steinhauser, I. M., Langer, K., Strebhardt, K. M. &Spankuch, B. Effect of trastuzumab-modified antisenseoligonucleotide-loaded human serum albuminnanoparticles prepared by heat denaturation. Biomaterials 29, 4022-4028 (2008).
217. Steinhauser, I., Langer, K., Strebhardt, K. &Spankuch, B. Uptake of plasmid-loaded nanoparticlesin breast cancer cells and effect on Plk1 expression. J. Drug Target. 17, 627-637 (2009).
218. Bandeiras, T. M. et al. Structure of wild-type Plk-1kinase domain in complex with a selective DARPin. Acta Crystallogr. D. Biol. Crystallogr. 64, 339-353(2008).
219. Nolen, B., Taylor, S. & Ghosh, G. Regulation of proteinkinases; controlling activity through activation segmentconformation. Mol. Cell 15, 661-675 (2004).
220. Cheng, K. Y., Lowe, E. D., Sinclair, J., Nigg, E. A. &Johnson, L. N. The crystal structure of the humanpolo-like kinase-1 polo box domain and itsphospho-peptide complex. EMBO J. 22, 5757-5768(2003).
221. García-Alvarez, B., de Cárcer, G., Ibañez, S., Bragado-Nilsson, E. & Montoya, G. Molecular and structuralbasis of polo-like kinase 1 substrate recognition:implications in centrosomal localization. Proc. NatlAcad. Sci. USA 104, 3107-3112 (2007).
222. Yun, S. M. et al. Structural and functional analyses ofminimal phosphopeptides targeting the polo-boxdomain of polo-like kinase 1. Nature Struct. Mol. Biol. 16, 876-882 (2009).
223. Leung, G. C. et al. The Sak polo-box comprises astructural domain sufficient for mitotic subcellularlocalization. Nature Struct. Biol. 9, 719-724 (2002).
224. Lu, L. Y. et al. Polo-like kinase 1 is essential for earlyembryonic development and tumor suppression. Mol. Cell Biol. 28, 6870-6876 (2008). This excellent report describes the structure andfunction of the PLK4 polo-box.
225. Kitada, K., Johnson, A. L., Johnston, L. H. & Sugino, A. A multicopy suppressor gene of the Saccharomycescerevisiae G1 cell cycle mutant gene dbf4 encodes aprotein kinase and is identified as CDC5. Mol. CellBiol. 13, 4445-4457 (1993).
226. Ohkura, H., Hagan, I. M. & Glover, D. M. Theconserved Schizosaccharomyces pombe kinase plo1,required to form a bipolar spindle, the actin ring, andseptum, can drive septum formation in G1 and G2cells. Genes Dev. 9, 1059-1073 (1995).
227. Liby, K. et al. Identification of the human homologueof the early-growth response gene Snk, encoding aserum-inducible kinase. DNA Seq. 11, 527-533(2001).
228. Karn, T. et al. Human SAK related to the PLK/polofamily of cell cycle kinases shows high mRNAexpression in testis. Onc. Rep. 4, 505-510 (1997).
229. Nothias, J. Y., Majumder, S., Kaneko, K. J. &DePamphilis, M. L. Regulation of gene expression atthe beginning of mammalian development. J. Biol. Chem. 270, 22077-22080 (1995).
230. Ko, M. A. et al. Plk4 haploinsufficiency causes mitoticinfidelity and carcinogenesis. Nature Genet. 37,883-888 (2005).
231. Casenghi, M. et al. Polo-like kinase 1 regulatesNlp, a centrosome protein involved in microtubulenucleation. Dev. Cell 5, 113-125 (2003).
232. Casenghi, M., Barr, F. A. & Nigg, E. A. Phosphorylationof Nlp by Plk1 negatively regulates its dyneindynactin-dependent targeting to the centrosome. J. Cell Sci. 118, 5101-5108 (2005).
233. Oshimori, N., Ohsugi, M. & Yamamoto, T. The Plk1target Kizuna stabilizes mitotic centrosomes to ensurespindle bipolarity. Nat. Cell Biol. 8, 1095-1101(2006).
234. De Luca, M., Lavia, P. & Guarguaglini, G. A functionalinterplay between Aurora-A, Plk1 and TPX2 at spindlepoles: Plk1 controls centrosomal localization ofAurora-A and TPX2 spindle association. Cell Cycle 5,296-303 (2006).
235. Kumagai, A. & Dunphy, W. G. Purification andmolecular cloning of Plx1, a Cdc25-regulatory kinasefrom Xenopus egg extracts. Science 273, 1377-1380(1996).
236. Roshak, A. K. et al. The human polo-like kinase, PLK,regulates cdc2/cyclin B through phosphorylation andactivation of the cdc25C phosphatase. Cell Signal 12,405-411 (2000).
237. Watanabe, N. et al. M-phase kinases inducephospho-dependent ubiquitination of somaticWee1 by SCFβ-TrCP. Proc. Natl Acad. Sci. USA 101,4419-4424 (2004).
238. Inoue, D. & Sagata, N. The polo-like kinase Plx1interacts with and inhibits Myt1 after fertilization ofXenopus eggs. EMBO J. 24, 1057-1067 (2005).
239. Jackman, M., Lindon, C., Nigg, E. A. & Pines, J. Active cyclin B1-Cdk1 first appears on centrosomesin prophase. Nature Cell Biol. 5, 143-148 (2003).
240. Yuan, J. et al. Cooperative phosphorylation includingthe activity of polo-like kinase 1 regulates thesubcellular localization of cyclin B1. Oncogene 21,8282-8292 (2002).
241. Yamashiro, S. et al. Myosin phosphatase-targetingsubunit 1 regulates mitosis by antagonizing polo-likekinase 1. Dev. Cell 14, 787-797 (2008).
242. van Vugt, M. A., Bras, A. & Medema, R. H. Restartingthe cell cycle when the checkpoint comes to a halt. Cancer Res. 65, 7037-7040 (2005).
243. Elowe, S., Hummer, S., Uldschmid, A., Li, X. &Nigg, E. A. Tension-sensitive Plk1 phosphorylationon BubR1 regulates the stability of kinetochoremicrotubule interactions. Genes Dev. 21, 2205-2219(2007).
244. Goto, H. et al. Complex formation of Plk1 and INCENPrequired for metaphase-anaphase transition. Nat. CellBiol. 8, 180-187 (2006).
245. Qi, W., Tang, Z. & Yu, H. Phosphorylation-and polobox-dependent binding of Plk1 to Bub1 is required forthe kinetochore localization of Plk1. Mol. Biol. Cell 17,3705-3716 (2006).
246. Ahonen, L. J. et al. Polo-like kinase 1 creates thetension-sensing 3F3/2 phosphoepitope and modulatesthe association of spindle-checkpoint proteins atkinetochores. Curr. Biol. 15, 1078-1089 (2005).
247. Sumara, I. et al. The dissociation of cohesin fromchromosomes in prophase is regulated by polo-likekinase. Mol. Cell 9, 515-525 (2002).
248. Riedel, C. G. et al. Protein phosphatase 2A protectscentromeric sister chromatid cohesion duringmeiosis I. Nature 441, 53-61 (2006).
249. Kitajima, T. S. et al. Shugoshin collaborates withprotein phosphatase 2A to protect cohesin. Nature441, 46-52 (2006).
250. Tang, Z. et al. PP2A is required for centromericlocalization of Sgo1 and proper chromosomesegregation. Dev. Cell 10, 575-585 (2006).
251. Hansen, D. V., Loktev, A. V., Ban, K. H. & Jackson,P. K. Plk1 regulates activation of the anaphasepromoting complex by phosphorylating andtriggering SCFβTrCP-dependent destruction of the APCinhibitor Emi1. Mol. Biol. Cell 15, 5623-5634(2004).
252. Moshe, Y., Boulaire, J., Pagano, M. & Hershko, A. Role of polo-like kinase in the degradation of earlymitotic inhibitor 1, a regulator of the anaphasepromoting complex/cyclosome. Proc. Natl Acad. Sci. USA 101, 7937-7942 (2004).
253. Eckerdt, F. & Strebhardt, K. Polo-like kinase 1:target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis. Cancer Res. 66,6895-6898 (2006).
254. Golan, A., Yudkovsky, Y. & Hershko, A. The cyclinubiquitinligase activity of cyclosome/APC is jointlyactivated by protein kinases Cdk1-cyclin B and Plk. J. Biol. Chem. 277, 15552-15557 (2002).
255. Kraft, C. et al. Mitotic regulation of the humananaphase-promoting complex by phosphorylation. EMBO J. 22, 6598-6609 (2003).
256. Nasmyth, K. Segregating sister genomes:the molecular biology of chromosome separation. Science 297, 559-565 (2002).
257. Alexandru, G., Uhlmann, F., Mechtler, K.,Poupart, M. A. & Nasmyth, K. Phosphorylationof the cohesin subunit Scc1 by Polo/Cdc5 kinaseregulates sister chromatid separation in yeast. Cell 105, 459-472 (2001).
258. Hornig, N. C. & Uhlmann, F. Preferential cleavageof chromatin-bound cohesin after targetedphosphorylation by polo-like kinase. EMBO J. 23,3144-3153 (2004).
259. Mishima, M., Kaitna, S. & Glotzer, M. Central spindleassembly and cytokinesis require a kinesin-likeprotein/RhoGAP complex with microtubule bundlingactivity. Dev. Cell 2, 41-54 (2002).
260. Mishima, M., Pavicic, V., Gruneberg, U., Nigg, E. A. & Glotzer, M. Cell cycle regulation of central spindleassembly. Nature 430, 908-913 (2004).
261. Burkard, M. E. et al. Plk1 self-organization andpriming phosphorylation of HsCYK-4 at the spindlemidzone regulate the onset of division in human cells. PLoS. Biol. 7, e1000111 (2009).
262. Brennan, I. M., Peters, U., Kapoor, T. M. & Straight, A. F. Polo-like kinase controls vertebrate spindle elongationand cytokinesis. PLoS. One. 2, e409 (2007).
263. Burkard, M. E. et al. Chemical genetics reveals therequirement for polo-like kinase 1 activity in positioningRhoA and triggering cytokinesis in human cells. Proc. Natl Acad. Sci. USA 104, 4383-4388 (2007).
264. Petronczki, M., Glotzer, M., Kraut, N. & Peters, J. M. Polo-like kinase 1 triggers the initiation of cytokinesisin human cells by promoting recruitment of theRhoGEF Ect2 to the central spindle. Dev. Cell 12,713-725 (2007).
265. Hutterer, A. et al. Mitotic activation of the kinaseAurora-A requires its binding partner bora. Dev. Cell11, 147-157 (2006).
266. Seki, A. et al. Plk1-and β-TrCP-dependent degradationof Bora controls mitotic progression. J. Cell Biol. 181,65-78 (2008).